Dr. Reddy’s Laboratories Ltd ADR (RDY) financial statements

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $10.9B

Dr. Reddy’s Laboratories Ltd ADR reported revenue of 325.5B INR in fiscal 2025, up 8.6% a year over 9 years.

Net income was 56.5B INR and the operating margin 22.1%, against 19.1% in 2016.

Free cash flow was 12.0B INR, and the company returned 6.7B INR in dividends and 1.4B INR in net buybacks.

Revenue and free cash flow

Fiscal years, $ billions (INR).

Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

<iframe src="https://investingly.io/embed/RDY/financials" width="100%" height="330" style="border:0;max-width:680px" title="Dr. Reddy’s Laboratories Ltd ADR revenue and free cash flow" loading="lazy"></iframe>
<p style="font-size:13px">Source: <a href="https://investingly.io/stocks/RDY/financials">Dr. Reddy’s Laboratories Ltd ADR financials</a> on Investingly</p>

Income statement

Fiscal years, in INR, from Dr. Reddy’s Laboratories Ltd ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	154.7B INR	140.8B INR	142.0B INR	153.9B INR	174.6B INR	189.7B INR	214.4B INR	245.9B INR	279.2B INR	325.5B INR
Cost of revenue	62.4B INR	62.5B INR	65.7B INR	70.4B INR	80.6B INR	86.6B INR	100.6B INR	106.5B INR	115.6B INR	135.1B INR
Gross profit	92.3B INR	78.4B INR	76.3B INR	83.4B INR	94.0B INR	103.1B INR	113.8B INR	139.3B INR	163.6B INR	190.4B INR
Research and development	17.8B INR	19.6B INR	18.3B INR	15.6B INR	15.4B INR	16.5B INR	17.5B INR	19.4B INR	22.9B INR	27.4B INR
Selling, general and admin	45.7B INR	46.4B INR	46.9B INR	48.7B INR	50.1B INR	54.6B INR	62.1B INR	68.0B INR	77.2B INR	93.9B INR
Operating income	29.6B INR	13.5B INR	11.9B INR	20.9B INR	16.0B INR	24.3B INR	29.5B INR	57.1B INR	67.7B INR	71.8B INR
Interest expense	826M INR	634M INR	788M INR	889M INR	983M INR	970M INR	958M INR	1.4B INR	1.7B INR	2.8B INR
Pre-tax income	27.1B INR	14.7B INR	14.3B INR	22.4B INR	18.0B INR	26.4B INR	32.3B INR	60.4B INR	71.9B INR	76.8B INR
Income tax	7.1B INR	2.6B INR	4.5B INR	3.6B INR	-1.5B INR	9.2B INR	8.7B INR	15.3B INR	16.2B INR	19.5B INR
Net income	20.0B INR	12.0B INR	9.8B INR	18.8B INR	19.5B INR	17.2B INR	23.6B INR	45.1B INR	55.7B INR	56.5B INR
EPS (diluted)	23.40 INR	14.42 INR	11.80 INR	22.62 INR	23.48 INR	20.73 INR	28.34 INR	54.17 INR	66.80 INR	67.78 INR
Diluted shares	855M	835M	831M	831M	830M	832M	832M	832M	834M	834M
Gross margin	59.6%	55.6%	53.7%	54.2%	53.8%	54.3%	53.1%	56.7%	58.6%	58.5%
Operating margin	19.1%	9.6%	8.4%	13.6%	9.2%	12.8%	13.7%	23.2%	24.3%	22.1%
Net margin	12.9%	8.5%	6.9%	12.2%	11.2%	9.1%	11.0%	18.3%	19.9%	17.4%

Balance sheet

Fiscal years, in INR, from Dr. Reddy’s Laboratories Ltd ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Cash and short-term investments	—	18.1B INR	21.0B INR	24.8B INR	25.7B INR	34.6B INR	44.4B INR	61.8B INR	81.5B INR	57.9B INR
Receivables	—	38.1B INR	40.6B INR	39.9B INR	50.3B INR	49.6B INR	66.8B INR	72.5B INR	80.3B INR	90.4B INR
Inventory	—	28.5B INR	29.1B INR	33.6B INR	35.1B INR	45.4B INR	50.9B INR	48.7B INR	63.6B INR	71.1B INR
Total current assets	—	100.4B INR	109.6B INR	114.5B INR	130.4B INR	148.2B INR	181.9B INR	204.3B INR	248.0B INR	250.1B INR
Property, plant and equipment	—	57.2B INR	57.9B INR	54.1B INR	52.3B INR	57.1B INR	62.2B INR	66.5B INR	76.9B INR	97.8B INR
Goodwill	—	3.8B INR	3.9B INR	3.9B INR	4.0B INR	4.6B INR	4.4B INR	4.2B INR	4.3B INR	11.8B INR
Total assets	—	219.8B INR	225.6B INR	225.4B INR	232.2B INR	265.5B INR	292.8B INR	321.9B INR	387.5B INR	493.0B INR
Total current liabilities	—	85.0B INR	69.7B INR	59.7B INR	72.8B INR	83.4B INR	94.0B INR	85.8B INR	96.0B INR	130.4B INR
Long-term debt	—	5.4B INR	25.1B INR	22.0B INR	1.3B INR	6.3B INR	5.7B INR	1.3B INR	6.0B INR	7.9B INR
Total liabilities	—	95.8B INR	99.1B INR	85.2B INR	77.3B INR	92.4B INR	102.3B INR	90.9B INR	107.0B INR	155.8B INR
Shareholders' equity	128.3B INR	124.0B INR	126.5B INR	140.2B INR	155.0B INR	173.1B INR	190.5B INR	231.0B INR	280.6B INR	333.4B INR
Net debt	—	45.1B INR	47.9B INR	31.9B INR	15.7B INR	14.6B INR	18.0B INR	2.9B INR	11.6B INR	31.3B INR

Cash flow

Fiscal years, in INR, from Dr. Reddy’s Laboratories Ltd ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	41.2B INR	21.5B INR	18.0B INR	28.7B INR	29.8B INR	35.7B INR	28.1B INR	58.9B INR	45.4B INR	46.4B INR
Capital spending	14.9B INR	41.0B INR	11.0B INR	8.4B INR	6.1B INR	12.6B INR	19.0B INR	18.9B INR	27.4B INR	34.4B INR
Free cash flow	26.4B INR	-19.5B INR	7.0B INR	20.3B INR	23.7B INR	23.1B INR	9.1B INR	40.0B INR	18.0B INR	12.0B INR
Stock-based compensation	442M INR	350M INR	454M INR	389M INR	521M INR	584M INR	592M INR	397M INR	407M INR	424M INR
Dividends paid	4.1B INR	3.4B INR	4.0B INR	4.0B INR	3.9B INR	4.1B INR	4.1B INR	5.0B INR	6.6B INR	6.7B INR
Share buybacks (net)	0 INR	-15.7B INR	0 INR	0 INR	-474M INR	-1.2B INR	0 INR	—	—	-1.4B INR
Net borrowing	—	—	882M INR	-15.1B INR	-18.7B INR	6.8B INR	3.5B INR	-19.4B INR	5.5B INR	24.5B INR
Free cash flow margin	17.0%	-13.8%	4.9%	13.2%	13.6%	12.2%	4.2%	16.3%	6.4%	3.7%
Dividends per share	4.80 INR	4.06 INR	4.80 INR	4.82 INR	4.72 INR	4.99 INR	4.99 INR	5.98 INR	7.98 INR	7.99 INR

Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RDY.

Open RDY in Investingly

Questions

What was Dr. Reddy’s Laboratories Ltd ADR's revenue in 2025?

325.5B INR in fiscal 2025, from its 10-K filing.

How much free cash flow does Dr. Reddy’s Laboratories Ltd ADR generate?

12.0B INR in fiscal 2025 (operating cash flow minus capital spending).

From Dr. Reddy’s Laboratories Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.